Previous Close | 16.85 |
Open | 16.80 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's Range | 16.80 - 17.45 |
52 Week Range | 7.30 - 18.75 |
Volume | 104,256 |
Avg. Volume | 310,366 |
Market Cap | 473.345M |
Beta | 1.09 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.94 |
Earnings Date | May 8, 2018 - May 14, 2018 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 32.67 |
NEW YORK, April 16, 2018-- Stemline Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel oncology therapeutics, today announced expansion of its Board of Directors to include ...
Stock Monitor: Cyclacel Pharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 09, 2018 / Active-Investors.com has just released a free research report on Stemline Therapeutics, Inc. (NASDAQ: STML ...
NEW YORK, April 05, 2018-- Stemline Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel oncology therapeutics, announced today that it has initiated its rolling submission of ...
NEW YORK, March 19, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
NEW YORK, March 19, 2018-- Stemline Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel oncology therapeutics, announced today that Ivan Bergstein, M.D., Stemline’ s CEO, will ...
On a per-share basis, the New York-based company said it had a loss of 93 cents. For the year, the company reported that its loss widened to $67.8 million, or $2.94 per share. Revenue was reported as $898,000. ...
NEW YORK, March 16, 2018--. Stemline Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel oncology therapeutics, announced today financial results for the quarter ended December ...
Stemline Therapeutics Inc’s (NASDAQ:STML): Stemline Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovering, acquiring, developing, and commercialization of proprietary oncology therapeutics in the United States. The US$504.11M market-capRead More...
NEW YORK, March 08, 2018-- Stemline Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for difficult to treat cancers, announced today that Ivan Bergstein, M.D., ...
High-growth stocks that are financially stable are attractive for many reasons. They provide a strong upside to your portfolio, with less likelihood of downside risks compared to less financially robustRead More...
NEW YORK, Jan. 26, 2018-- Stemline Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel oncology therapeutics, today announced the closing of a previously announced underwritten ...
Newman Ferrara LLP announced today that the firm is conducting an investigation on behalf of shareholders of Stemline Therapeutics Inc. into potential breaches of fiduciary duty by the Company’s Board of Directors .
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Stemline Therapeutics, Inc. Here are 5 ETFs with the largest exposure to STML-US. Comparing the performance and risk of Stemline Therapeutics, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
Most investors find it challenging to find companies with prospective double-digit growth rates that are also financially robust. These hidden gems also add meaningful upside to a portfolio, should theRead More...
Categories: Yahoo FinanceGet free summary analysis Stemline Therapeutics, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of Stemline Therapeutics, Inc. – Cyclacel Pharmaceuticals, Inc., Verastem, Inc., Agenus Inc., Celgene Corporation, Sunesis Pharmaceuticals, Inc., OncoMed Pharmaceuticals, Inc., Pfizer Inc. and ImmunoCellular Therapeutics, Ltd. (CYCC-US, VSTM-US, AGEN-US, ... Read more (Read more...)
The New York-based company said it had a loss of 68 cents per share. The results missed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a ...